Ocugen (OCGN) to Release Quarterly Earnings on Wednesday

Ocugen (NASDAQ:OCGN) will likely be issuing its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.86 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 8:30 AM ET.

Ocugen Stock Up 6.6%

Ocugen stock opened at $1.94 on Tuesday. The company has a debt-to-equity ratio of 8.04, a quick ratio of 1.85 and a current ratio of 1.85. Ocugen has a fifty-two week low of $0.52 and a fifty-two week high of $1.96. The business’s 50-day simple moving average is $1.55 and its two-hundred day simple moving average is $1.41. The company has a market cap of $605.90 million, a PE ratio of -8.82 and a beta of 2.75.

Hedge Funds Weigh In On Ocugen

Several large investors have recently modified their holdings of the business. Jain Global LLC lifted its holdings in Ocugen by 7.2% during the 4th quarter. Jain Global LLC now owns 114,690 shares of the company’s stock worth $155,000 after buying an additional 7,686 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Ocugen by 56.7% during the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock worth $36,000 after acquiring an additional 13,326 shares during the period. SmartHarvest Portfolios LLC purchased a new stake in shares of Ocugen during the fourth quarter worth $31,000. NewEdge Advisors LLC raised its stake in shares of Ocugen by 198.0% in the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock valued at $36,000 after acquiring an additional 24,460 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Ocugen in the fourth quarter valued at $38,000. Institutional investors and hedge funds own 10.27% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on the company. Chardan Capital reissued a “buy” rating and issued a $7.00 price objective on shares of Ocugen in a report on Tuesday, January 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $7.00.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.